Unicycive Therapeutics Inc Stock Price, News & Analysis

Unicycive Therapeutics (Nasdaq: UNCY) has announced that Dr. Shalabh Gupta, CEO, will present at two investor conferences in March 2022. The first is the 34th Annual ROTH Conference from March 13-15, where Dr. Gupta will offer an online presentation and participate in one-on-one meetings. The second event is the Maxim Group 2nd Annual Virtual Growth Conference on March 28 at 1:00 pm Eastern Time, featuring a fireside chat format. Unicycive is focused on developing innovative therapies for kidney diseases, including its lead drug Renazorb.

Unicycive Therapeutics (Nasdaq: UNCY) announced that two abstracts highlighting the efficacy and safety of Renazorb (lanthanum dioxycarbonate) will be presented at the National Kidney Foundation (NKF) Spring Clinical Meeting from April 6-10, 2022, in Boston. Renazorb aims to treat hyperphosphatemia in chronic kidney disease patients, utilizing advanced nanoparticle technology for better phosphate binding. The data presented will support Renazorb's potential as a leading phosphate binder with fewer dosage pills required.

Unicycive Therapeutics, a clinical stage biotechnology company focused on kidney disease therapies, announced that CEO Shalabh Gupta will present at the H.C. Wainwright BIOCONNECT Virtual Conference from January 10-13, 2022. The presentation can be accessed on the company's website under the Investors section starting January 10, 2022, at 7:00 a.m. ET. Unicycive is developing innovative treatments, including Renazorb, a phosphate binding agent for hyperphosphatemia, and UNI-494, a new chemical entity in late preclinical development for acute kidney injury.

Unicycive Therapeutics (Nasdaq: UNCY) announced progress on Renazorb, a second-generation phosphate binding agent for hyperphosphatemia in chronic kidney disease patients. Following a Type C interaction, the FDA confirmed the drug's comparability to Fosrenol and endorsed the 505(b)(2) NDA submission pathway based on a clinical bioequivalence study. The upcoming study will include a comparator arm with Fosrenol. Unicycive plans to file the NDA in Q4 2022, indicating readiness to proceed with the remaining study.

Unicycive Therapeutics (Nasdaq: UNCY) reported its Q3 2021 financial results, showing a net loss of $5.2 million, or $0.37 per share, a dramatic rise from a $0.7 million loss in Q3 2020. Key developments include the addition to the Russell Microcap Index and the hiring of Douglas Jermasek as Executive VP of Corporate Strategy. The company anticipates confirmatory guidance from the FDA regarding its lead drug, Renazorb, aimed at treating hyperphosphatemia in chronic kidney disease, in Q4 2021.

Unicycive Therapeutics, a clinical-stage biotechnology firm focused on kidney disease therapies, has appointed Douglas Jermasek as Executive Vice President, Corporate Strategy. Jermasek brings over 25 years of industry experience, including significant roles at Akebia and Genzyme, where he drove over $1 billion in sales. His expertise in kidney disease therapy is expected to enhance Unicycive’s corporate and commercial strategies. This appointment signals the company’s commitment to addressing challenges in kidney care and advancing its lead drug, Renazorb, aimed at treating hyperphosphatemia.

Unicycive Therapeutics, Inc. (Nasdaq: UNCY) will be added to the Russell Microcap® Index on September 20, 2021, enhancing its visibility and recognition within the investment community. This membership, which lasts for one year, will link Unicycive with over $17.9 trillion in assets benchmarked to Russell indexes. CEO Shalabh Gupta emphasized that this milestone will drive further interest in Unicycive's clinical programs as a newly public company. The inclusion reflects Unicycive's market-capitalization ranking and style attributes determined by FTSE Russell.

Unicycive Therapeutics, a clinical stage biotechnology firm focused on kidney disease therapies, announced that CEO Shalabh Gupta will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. A webcast link will be available on the Unicycive website's Investors section on September 13, with an archive accessible for three months. Unicycive's lead drug, Renazorb, targets hyperphosphatemia, while UNI-494 is in late preclinical development for acute kidney injury. For further details, visit www.unicycive.com.

Unicycive Therapeutics, a clinical-stage biotechnology firm focused on kidney disease treatments, disclosed its Q2 2021 financial results. The company raised $25 million from its recent IPO and plans to meet the FDA in Q4 2021 regarding its lead product Renazorb. R&D expenses increased to $0.5 million from $0.2 million year-over-year, and net loss rose to $1.1 million or $0.13 per share. The company is working on the investigational drug UNI-494 and expects significant milestones in the upcoming periods.